{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:30:32Z","timestamp":1765546232601},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["epilepsybehavior.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.yebeh.2017.05.010","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T22:16:39Z","timestamp":1497996999000},"page":"166-172","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Association between switching antiepileptic drug products and healthcare utilization: A systematic review"],"prefix":"10.1016","volume":"73","author":[{"given":"Patrick","family":"Kwan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Palmini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2017.05.010_bb0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/nedt.2007.3.1.117","article-title":"Managing patient adherence and quality of life in epilepsy","volume":"3","author":"Eatock","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0010","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1185\/030079907X199673","article-title":"Management of breakthrough seizures in the emergency department: continuity of patient care","volume":"23","author":"Montouris","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0015","first-page":"392","article-title":"Overview of drugs used for epilepsy and seizures - etiology, diagnosis and treatment","volume":"35","author":"Goldenberg","year":"2010","journal-title":"P T"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.0013-9580.2004.455005.x","article-title":"The use of antiepileptic drugs\u2014principles and practice","volume":"45","author":"Sander","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0025","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2165\/10898530-000000000-00000","article-title":"Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis","volume":"70","author":"Kesselheim","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0030","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/TCRM.S5366","article-title":"Substitution of anticonvulsant drugs","volume":"5","author":"Steinhoff","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0035","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.yebeh.2007.03.014","article-title":"Current approaches to the use of generic antiepileptic drugs","volume":"11","author":"Kramer","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0040","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.yebeh.2004.05.011","article-title":"Therapeutic equivalency of generic antiepileptic drugs: results of a survey","volume":"5","author":"Wilner","year":"2004","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0045","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1177\/106002809703100504","article-title":"Comparative study of bioavailability and clinical efficacy of carbamazepine and epileptic patients","volume":"31","author":"Silpakit","year":"1997","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0050","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.clinthera.2007.02.005","article-title":"Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy","volume":"29","author":"Makus","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0055","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1755-5949.2010.00210.x","article-title":"Switching from brand-name to generic psychotropic medications: a literature review","volume":"17","author":"Desmarais","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0060","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1177\/106002809202600605","article-title":"Loss of seizure control associated with generic substitution of carbamazepine","volume":"26","author":"Welty","year":"1992","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1059-1311(96)80013-6","article-title":"Generic prescription for epilepsy. Is it safe?","author":"Crawford","year":"1996","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0070","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1212\/WNL.43.12.2696","article-title":"Carbamazepine toxicity resulting from generic substitution","volume":"43","author":"Gilman","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0075","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00044011-199918010-00003","article-title":"Clinical problems with generic antiepileptic drugs","volume":"18","author":"Mayer","year":"1999","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0080","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/j.1875-9114.2012.01099.x","article-title":"Efficacy and safety of innovator versus generic drugs in epilepsy: a systematic review","volume":"32","author":"Talati","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0085","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1212\/WNL.0b013e3181aa5300","article-title":"The risks and costs of multiple-generic subs of topiramate","volume":"72","author":"Duh","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0090","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1212\/01.wnl.0000313154.55518.25","article-title":"Clinical consequences of generic substitution of lamotrigine for patients with epilepsy","volume":"70","author":"LeLorier","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0095","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1528-1167.2008.01703.x","article-title":"Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes","volume":"50","author":"Zachry","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0100","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1586\/ern.10.163","article-title":"Generic substitution of antiepileptic drugs","volume":"10","author":"Sander","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0105","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.eplepsyres.2013.04.010","article-title":"Bioequivalent antiepileptic drug switching and the risk of seizure-related events","volume":"106","author":"Hansen","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0110","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1517\/17425255.2015.989211","article-title":"Is bioavailability altered in generic versus brand anticonvulsants?","volume":"11","author":"Jankovic","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0115","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40263-013-0112-8","article-title":"Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations","volume":"28","author":"Karalis","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0120","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.eplepsyres.2011.09.019","article-title":"Changed constitution without change in brand name\u2014the risk of generics in epilepsy","volume":"98","author":"Patel","year":"2012","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0125","series-title":"Formulation switching of antiepileptic drugs: a report on the recommendations of the Commission on Human Medicines from July 2013","author":"MHRA","year":"2013"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0130","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1185\/03007990903488704","article-title":"Acute epilepsy exacerbations in patients switched between A-rated anti-epileptic drugs","volume":"26","author":"Devine","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0135","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1528-1167.2011.03130.x","article-title":"Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy","volume":"52","author":"Erickson","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0140","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/clpt.2010.90","article-title":"Refilling and switching of antiepileptic drugs and seizure-related events","volume":"88","author":"Gagne","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0145","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.yebeh.2009.05.019","article-title":"Association between antiepileptic drug switching and epilepsy-related events","volume":"15","author":"Hansen","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0150","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1212\/WNL.0b013e3181df091b","article-title":"Generic antiepileptic drugs and associated medical resource utilization in the United States","volume":"74","author":"Labiner","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0155","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1185\/03007990903044374","article-title":"Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries","volume":"25","author":"Paradis","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0160","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/pds.3879","article-title":"Brand name to generic substitution of antiepileptic drugs does not lead to seizure-related hospitalization: a population-based case-crossover study","volume":"24","author":"Polard","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0165","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1592\/phco.29.7.769","article-title":"Effects of anti-epileptic drug substitutions on epileptic events requiring acute care","volume":"29","author":"Rascati","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0170","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s40263-014-0191-1","article-title":"Factors associated with seizure recurrence in epilepsy patients treated with antiepileptic monotherapy: a retrospective observational cohort study using US administrative insurance claims","volume":"28","author":"Shcherbakova","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0175","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1345\/aph.1Q349","article-title":"Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies","volume":"45","author":"Yamada","year":"2011","journal-title":"Ann Pharmacother"},{"issue":"iii-x","key":"10.1016\/j.yebeh.2017.05.010_bb0180","first-page":"1","article-title":"Evaluating non-randomised intervention studies","volume":"7","author":"Deeks","year":"2003","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0185","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/epi.13057","article-title":"Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics","volume":"56","author":"Wilmshurst","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0190","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1212\/WNL.0000000000003259","article-title":"Switching generic antiepileptic drug manufacturer not linked to seizures: a case-crossover study","volume":"87","author":"Kesselheim","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0195","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/bcp.12298","article-title":"Substandard drugs: a potential crisis for public health","volume":"78","author":"Johnston","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0200","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S1474-4422(16)00014-4","article-title":"Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial","volume":"15","author":"Privitera","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0205","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/epi.13095","article-title":"Generic lamotrigine versus brand-name lamictal bioequivalence in patients with epilepsy: a field test of the FDA bioequivalence standard","volume":"56","author":"Ting","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0210","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1212\/01.wnl.0000259400.30539.cc","article-title":"Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy","volume":"68","author":"Liow","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0215","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1528-1167.2006.00871.x","article-title":"Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs","volume":"47","author":"Perucca","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.05.010_bb0220","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1528-1167.2010.02573.x","article-title":"Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability","volume":"51","author":"Bialer","year":"2010","journal-title":"Epilepsia"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505017300720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505017300720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T18:59:21Z","timestamp":1535741961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505017300720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":44,"alternative-id":["S1525505017300720"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2017.05.010","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between switching antiepileptic drug products and healthcare utilization: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2017.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}